Why Generic AI Falls Short in Pharma and What Sinequa Delivers Instead

The pharmaceutical industry has been promised more from AI than almost any other. The opportunity is real: McKinsey estimates that generative AI could unlock up to $110 billion in annual value for pharma, with as much as $25 billion in clinical development alone. But realizing that value requires more than deploying a capable AI model. It requires deploying the right data foundation — one that makes the model’s outputs accurate, auditable, and grounded in the organization’s own verified knowledge rather than in the public internet or general training data.

This is where the gap between generic AI tools and purpose-built pharma AI becomes commercially significant. And it is the gap that Sinequa’s enterprise agentic AI platform is built to close.

The Pharma Data Problem Generic AI Cannot Solve

Pharmaceutical R&D depends on massive volumes of highly specialized, highly fragmented data. Scientific publications, clinical study reports, investigator notes, regulatory submissions, EHRs, imaging data, omics datasets, real-world evidence, and decades of internal research documentation — all of it relevant, none of it accessible through a single system, and most of it in formats that general-purpose AI tools were not designed to handle.

When a pharmaceutical researcher asks a generic AI tool — Microsoft Copilot, ChatGPT, or a legacy enterprise search system — for intelligence on a compound’s development history, the tool faces a structural problem: it can only answer based on what it has access to. General-purpose LLMs draw on internet training data, which means they cannot access internal clinical data, proprietary compound research, or unpublished regulatory correspondence. Legacy search systems find documents but cannot synthesize them. And tools that are not trained on biomedical terminology routinely misinterpret scientific queries — retrieving documents where search terms appear rather than documents where the relevant scientific concepts are present.

The result is a technology that fails at the exact moments when accuracy matters most: during compound selection, regulatory preparation, and safety signal analysis — decisions where an incorrect or incomplete answer has consequences that extend well beyond the organization.

What Makes Sinequa Different in Life Sciences

Scientific Language at the Depth Pharma Requires

Generic AI tools treat scientific language as text. Sinequa treats it as ontology.

Enterprise AI search purpose-built for life sciences understands the structured semantic relationships between biomedical entities — drugs, targets, genes, disease indications, clinical endpoints — in the way that pharmaceutical scientists understand them. A query about a kinase inhibitor retrieves documents referencing the compound by all of its synonyms and nomenclature variants. A query about a safety signal resolves the clinical terminology to find documents where the relevant adverse event is described using different but equivalent language. An expert discovery query surfaces the scientists with relevant documented expertise based on what they have actually published and contributed to, not what their organizational profile claims.

This scientific semantic depth is the foundation of everything else. A system that cannot retrieve accurately cannot synthesize accurately. And in pharmaceutical applications where incomplete retrieval means incomplete intelligence, the scientific language layer is the prerequisite for any of the other capabilities to deliver their full value.

RAG Grounding — Eliminating Hallucination in GxP Contexts

The hallucination problem in general-purpose AI is a nuisance in most enterprise contexts and a compliance risk in pharmaceutical ones. When an AI system generates regulatory submission content, safety analyses, or clinical intelligence that includes findings not grounded in the organization’s actual data, the output is not just inaccurate — it is potentially a GxP violation.

Advanced RAG addresses this architecturally. Rather than generating responses from general training data, Sinequa retrieves the relevant content from the organization’s own verified sources — ELNs, LIMS, SAS clinical databases, regulatory archives, licensed scientific literature — and uses that content as the factual basis for every AI-generated response. The LLM cannot hallucinate findings from a study it has not retrieved. Every synthesized output includes citations to the specific source documents that grounded it, enabling the human review that GxP workflows require and providing the audit trail that regulatory frameworks demand.

This is not just a safety feature — it is the capability that makes AI usable for regulatory document generation, clinical intelligence synthesis, and pharmacovigilance analysis. Without it, pharmaceutical organizations are limited to using AI in low-stakes workflows where inaccuracy is tolerable. With it, AI becomes genuinely deployable across the workflows that drive the most value.

For deeper technical context on how this works in practice, the RAG-based approaches for life sciences applications guide covers the architecture in detail.

Trusted, Explainable Intelligence — Not Black-Box Output

Explainability in pharmaceutical AI is not a preference — it is a regulatory requirement. Any AI system used in a GxP-relevant workflow must be able to show its work: where did this insight come from, which source documents were used, and what would need to change for the conclusion to change? Black-box AI systems that generate outputs without traceable provenance cannot meet this requirement, regardless of how accurate their outputs appear.

Sinequa’s platform delivers full transparency into how insights are generated. Every AI-synthesized response includes source citations. Every retrieved document can be traced to its origin system. Every access decision is logged and auditable. This transparency is not a limitation on AI capability — it is the architecture that makes AI capability deployable in a regulated environment without creating compliance exposure.

Enterprise Security Built for Life Sciences Data Governance

Pharmaceutical organizations operate under information governance requirements that have no parallel in most enterprise AI contexts: patient privacy obligations (HIPAA, GDPR), IP protection for proprietary compound research, pre-submission regulatory confidentiality, and in some programs, export control regulations for certain technical data.

Sinequa’s enterprise security architecture enforces access controls at the retrieval layer — not as a post-processing filter, but at the point where data is selected for inclusion in any AI-generated response. A researcher cannot receive an AI synthesis that incorporates data they are not authorized to access, regardless of how the query is phrased. This retrieval-layer enforcement supports HIPAA, GDPR, and GxP compliance without requiring pharmaceutical organizations to limit AI deployments to sanitized data subsets.

The distinction from general-purpose tools is direct: Microsoft Copilot and ChatGPT are not designed for retrieval-layer access control in regulated environments. Their governance models were built for general enterprise use and adapted for compliance. Sinequa’s security architecture was designed for regulated industry requirements from the ground up.

Unified Access Across the Full Pharma Data Environment

The most valuable pharmaceutical intelligence is distributed across systems that were never designed to interoperate. ELNs capture experimental records. LIMS systems hold analytical data. SAS databases contain clinical trial data. Document management platforms hold regulatory submissions. Legacy archives contain historical program documentation. Licensed databases hold the external scientific literature. Public regulatory databases hold approval history and agency guidance.

No general-purpose AI tool connects to all of these simultaneously. Legacy enterprise search connects to some of them but cannot synthesize intelligently across them. Sinequa connects to the full environment — private internal systems, licensed scientific content, and public regulatory sources — enabling pharmaceutical researchers and regulatory specialists to query the complete knowledge base relevant to any scientific or regulatory question from a single interface.

Where Value Concentrates Across the Drug Development Lifecycle

Discovery and target identification. Sinequa enables researchers to query the full internal compound history alongside the external scientific and patent landscape simultaneously — surfacing competitive intelligence, prior art, and mechanistic insights that inform compound selection before significant investment is committed. Drug repositioning opportunities that would previously have required weeks of manual analysis are identified through AI-powered synthesis in hours.

Clinical development. Trial design decisions benefit from access to the full cross-trial patient data the organization has accumulated — not just metadata summaries, but actual patient-level data across hundreds of criteria simultaneously. Protocol teams design more precise, evidence-grounded studies. Enrollment is accelerated by AI-powered matching of patient criteria against trial eligibility profiles across site networks.

Regulatory affairs. Regulatory teams preparing submissions or responding to agency queries have access to the full prior submission history, agency correspondence, and competitive approval intelligence through natural language queries — compressing preparation timelines and strengthening submissions with comprehensive evidentiary support.

Pharmacovigilance and real-world evidence. Post-market safety surveillance powered by AI agents monitoring adverse event databases, literature, and real-world evidence continuously — surfacing potential safety signals for human review faster and more comprehensively than manual monitoring programs allow.

The Strategic Argument for Purpose-Built Pharma AI

Generic AI tools will continue to improve. But the pharmaceutical industry’s specific requirements — scientific semantic depth, GxP-compliant grounding, retrieval-layer access control, and unified connectivity across the full life sciences data environment — are not features that general-purpose tools are converging toward. They are architectural decisions made for the specific complexity of pharmaceutical data environments, and they determine whether AI deployments produce the results documented above or remain confined to low-stakes workflows where their limitations do not matter.

Sinequa is not a generic AI tool adapted for life sciences. It is an enterprise AI platform built for the data environments where pharmaceutical decisions are made — and the results at UCB, Pfizer, AstraZeneca, GSK, Novartis, and a global biopharma leader with 500 million documents reflect what that difference delivers in production.